Insulet Co. (NASDAQ:PODD) Given Average Recommendation of "Moderate Buy" by Analysts

Insulet Co. (NASDAQ:PODD - Get Free Report) has earned an average rating of "Moderate Buy" from the seventeen brokerages that are presently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and fourteen have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $292.06.

Several equities research analysts have recently weighed in on PODD shares. TD Cowen upped their price target on shares of Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a research report on Friday, January 3rd. Raymond James reaffirmed an "outperform" rating and set a $328.00 target price (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. Canaccord Genuity Group boosted their price target on Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Royal Bank of Canada initiated coverage on Insulet in a research report on Thursday, March 6th. They set an "outperform" rating and a $340.00 price objective on the stock. Finally, Piper Sandler boosted their target price on shares of Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a report on Friday, February 21st.

Insider Transactions at Insulet

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the transaction, the director now directly owns 3,231 shares in the company, valued at $888,525. This trade represents a 36.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.47% of the company's stock.

Hedge Funds Weigh In On Insulet

Hedge funds and other institutional investors have recently bought and sold shares of the business. SBI Securities Co. Ltd. acquired a new stake in shares of Insulet in the fourth quarter worth $36,000. Itau Unibanco Holding S.A. acquired a new stake in Insulet during the fourth quarter worth about $42,000. SRS Capital Advisors Inc. raised its position in Insulet by 43.1% during the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after acquiring an additional 56 shares in the last quarter. Friedenthal Financial acquired a new position in Insulet in the fourth quarter valued at approximately $57,000. Finally, Assetmark Inc. increased its holdings in shares of Insulet by 1,447.1% during the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after purchasing an additional 246 shares in the last quarter.

Insulet Stock Up 2.3 %

Shares of NASDAQ:PODD opened at $244.02 on Wednesday. The business's 50 day moving average is $261.71 and its 200 day moving average is $261.16. The stock has a market cap of $17.14 billion, a P/E ratio of 42.15, a price-to-earnings-growth ratio of 3.62 and a beta of 1.30. Insulet has a 52-week low of $160.19 and a 52-week high of $289.46. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.00 by $0.15. The business had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. Sell-side analysts predict that Insulet will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.